AstraZeneca: exclusive licensing agreement with Alteogen

(CercleFinance.com) - AstraZeneca announces that it has entered into an exclusive licensing agreement with Alteogen for ALT-B4, an innovative hyaluronidase based on Hybrozyme platform technology.


Under this agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialize subcutaneous formulations of several oncology treatments.

Alteogen will be responsible for the clinical and commercial supply of ALT-B4 to AstraZeneca.

AstraZeneca will make an upfront payment to Alteogen, as well as additional payments based on the achievement of specific development, regulatory and sales milestones. Alteogen will also receive royalties on sales of commercialized products.

This transaction has no impact on AstraZeneca's financial forecasts for 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.